The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

Inclusion Criteria: * 18 to 70 years of age inclusive with the diagnosis of asthma based on Global Strategy for Asthma Management and Prevention (GINA) 2019 at the time of signing the informed consent * History of ≥1 exacerbation(s) in the previous year * Uncontrolled moderate to severe asthma (ACQ-5 ≥1.5) at visit (V)1 and V2, prior to randomization * Pre-bronchodilator FEV1 ≤80% of predicted normal at V1 and V2, prior to randomization * Exhibit bronchodilator reversibility (≥12% and 200 mL improvement in FEV1 post SABA administration) during screening, prior to randomization * Blood eosinophil ≥300 cells /µL and FeNO ≥25 ppb during screening, prior to randomization NOTES: * Historical values of blood eosinophil count meeting the eligibility criterion measured within 6 months prior to SV1 in the absence of OCS treatment are allowed. * FeNO value to be checked for eligibility at V2 as well. -Existing treatment with medium to high dose ICS in combination with a second controller (e.g. LABA, LTRA) ± a third controller. The dose regimen should be stable ≥1 month prior V1 and during screening. Exclusion Criteria: * Current smoker (cigarette or e-cigarette) or cessation of smoking within 1 year prior randomization * Previous smoker with a smoking history \>10 pack-years * Known hypersensitivity to dupilumab or any of its excipients * A subject who experiences an asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due …